NOTCH1 and medulloblastoma: As a result, the intrathecal administration of anti-NOTCH1 Negative Regulatory Region antibody (anti-NRR1) in mice bearing group 3 medulloblastomas resulted in an attenuation of the metastatic potential of these tumors and a survival advantage for the treated mice [120].